CordenPharma Completes Colorado HPAPI Lab Expansion
20th October 2020
CordenPharma has announced the completion of a new laboratory for highly potent active pharmaceutical ingredients (HPAPIs) in its Boulder, Colorado facility. CordenPharma Colorado, a former Pfizer facility acquired by the German CDMO in 2017, has extensive experience and capabilities in the development and manufacturing of high-potency APIs from clinical to commercial scale.
The acquisition of the Boulder facility three years ago is aligned with a broader corporate strategy of the pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), CordenPharma, of offering fully integrated supply (APIs, drug products, packaging, and logistics), including development and manufacturing of highly potent and oncology products.
Michael Quirmbach, CEO & President, CordenPharma, explains in a recent CHEManager interview: “Over the last few years, we have expanded our capabilities by both heavily investing in technology, development and manufacturing capacity expansion, as well as through focused acquisitions. As it relates to the latter, we carefully analyze the assets with a clear focus and ask ourselves if this adds value to our service offering, and ultimately to our customers. All this has been achieved through the strong commitments by our shareholder International Chemical Investors Group.
The new laboratory is capable of handling highly potent compounds with an OEL as low as 1ng/m3 and is already available to customers.
“Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” comments Jason Bertola, Director of CordenPharma’s Global Highly Potent & Oncology Platform.
For more information visit www.chemanager-online.com/en